

Molecular Structural Requirements for the Dual Inhibition of Mdm2 and Mdm4 for Discovery of Novel Anticancer Agents

Suprava Shah, Surendra K. Nayak, Gopal Lal Khatik, Rakesh Narang

Department of Pharmaceutical Chemistry, Lovely Professional University, Phagwara, Punjab, India

E-mail: Shahsuprava1@gmail.com, surendra_niper@yahoo.com

INTRODUCTION

Mdm2 belonging to the E3 ubiquitin family degrades the p53 protein which is a natural tumor suppressor whereas Mdm4, being highly homologous to Mdm2, inhibit the transcriptional activity of p53. High dose of non selective and genotoxic drugs may induce p53 independent pathways and thus cause severe toxicities in normal tissues. As a result, dual inhibitors of Mdm2/ Mdm4 will result in the formation of selective and non-genotoxic agent.








Figure 1: Structure of p53, Mdm2 (PDB id 1YCR) and Mdm4 (PDB id 3DAB).

OBJECTIVES


Mdm2/X pharmacological inhibitors to activate the p53 pathway and challenge cancer is an appealing and fruitful therapeutic strategy. The main aim of the study is to identify the structural characteristics of a lead molecule for dual inhibition of Mdm2 and Mdm4.

SUBSTITUENT FOR DUAL INHIBITION




Mdm2 Inhibitors



Dual Inhibitors




Mdm4 Inhibitors



Functional groups of Dual inhibitors

- Phenyl ring
- Pyrrole
- Ethanol



Mdm2 Inhibitors-Functional Groups		Mdm4 Inhibitors- Functional Groups	
Nutlin 3a	Phenyl ring, Chlorobenzyl, Imidazole, Piperazine	SJ-17750	Phenyl ring, Chlorobenzyl, Carboxyl group
HDM201	Chlorobenzyl, Piperidine, Butanone	WK-298	Phenyl ring, Chlorobenzyl, Pyrrole, Pyrrolidone
AM8553	Chlorobenzyl, Two fused pyrrole ring, 5-chloropyridin-2-one	XI-006	Piperidine, Phenyl ring, Nitrogen dioxide
AMG232	Chlorobenzyl, Toluene, Piperidine, Carboxylic group		

CHARACTERISTICS OF DUAL INHIBITORS

- Phenyl ring
- Pyrrole ring

CONCLUSION

Mdm2/X are two key regulators of the tumor suppressor p53 whose over expression disables p53 and causes cancer. Therefore to get the better therapeutic activity simultaneous inhibition is proposed.

SELECTED REFERENCES

1. Macchiarulo A. et al., Expanding the horizon of chemotherapeutic targets: From Mdm2 to MdmX (Mdm4), The Royal Society of Chemistry, 2011, 2, 455-465
2. Graves B. et al., Activation of the p53 pathway of small molecule induced Mdm2 and MdmX dimerization, PNAS, 2012, 109, 11789-11790
3. Zhao Y. et al., Small molecule inhibitors of the Mdm2-p53 protein-protein interaction (Mdm2 Inhibitors) in clinical trials for Cancer treatment, Journal of Medicinal Chemistry, 2015, 58(3), 1038-1052
4. Sores J. et al., DIMP53-1 : A novel small molecule dual inhibitor of p53-Mdm2/X interaction with multifunctional p53 dependent anticancer properties, Molecular Oncology, 2017, 11(6), 612-627